Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of LP-003 injection in chronic rhinosinusitis with nasal polyps
CTR20255065Phase 2Active
- Sponsor
- LongBio Pharma
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LP-003 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by LongBio Pharma. Started Dec 2025; status: active.
02
Drugs
LP-003
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20255065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255065.